Bile duct carcinomas (cholangiocarci-noma) are devastating tumors. Surgical resection is the mainstay of current treatment; however, it is only effective for a limited number of patients diagnosed at early stages of the disease. Unfortunately, the vast majority of patients seek treatment of the advanced disease making them poor candidates for curative surgery. Conventional chemotherapy and radiation therapy have not been shown to be effective in prolonging long-term survival of patients with cholangiocarcinoma. In addition, there are no sensitive and specific tests to diagnose and exclude this disease in high-risk populations. Thus, there is an urgent need for novel biomarkers and therapies based on a better understanding of biliary tumorigenesis that would significantly impact the disease outcome. This chapter reviews current clinical data on the p53 protein family and its role in biliary tumorigenesis.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Ahrendt, S.A., Rashid, A., Chow, J.T., Eisenberger, C.F., Pitt, H.A., and Sidransky, D. 2000. p53 overexpression and K-ras gene mutations in primary sclerosing cholangitis-associated biliary tract cancer. J. HepatoBiliary-Pancreat. Surg. 7: 426–431.
Albores-Saavedra, J., Henson, D.E., and Klimstra, D.S. 2000. Tumors of the Gall bladder, Extrahepatic Bile Ducts and Ampulla of Vater. Atlas of Tumor Pathology, Armed Forces Institute of Pathology, Washington, DC.
Argani, P., Shaukat, A., Kaushal, M., Wilentz, R.E., Su, G.H., Sohn, T.A., Yeo, C.J., Cameron, J.L., Kern, S.E., and Hruban, R.H. 2001. Differing rates of loss of DPC4 expression and of p53 overexpression among carcinomas of the proximal and distal bile ducts. Cancer 91: 1332–1341.
Choi, B.I., Han, J.K., Hong, S.T., and Lee, K.H. 2004. Clonorchiasis and cholangiocarcinoma: etiologic relationship and imaging diagnosis. Clin. Microbiol. Rev. 17: 540–552.
Concin, N., Becker, K., Slade, N., Erster, S., Mueller-Holzner, E., Ulmer, H., Daxenbichler, G., Zeimet, A., Zeillinger, R., Marth, C., and Moll, U.M. 2004. Transdominant DeltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo. Cancer Res. 64: 2449–2460.
Diamantis, I., Karamitopoulou, E., Perentes, E., and Zimmermann, A. 1995. p53 protein immunoreactivity in extrahepatic bile duct and gallbladder cancer: correlation with tumor grade and survival, Hepatology 22: 774–779, Baltimore, MD.
Farazi, P.A., Zeisberg, M., Glickman, J., Zhang, Y., Kalluri, R., and DePinho, R.A. 2006. Chronic bile duct injury associated with fibrotic matrix microenvironment provokes cholangiocarci-noma in p53-deficient mice. Cancer Res. 66: 6622–6627.
Flores, E.R., Sengupta, S., Miller, J.B., Newman, J.J., Bronson, R., Crowley, D., Yang, A., McKeon, F., and Jacks, T. 2005. Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell 7: 363–373.
Green, F.L., Page, D.L., Fleming, I.D., Fritz, A.G., Balch, C.M., Haller, D.G., and Morrow, M. 2002. AJCC Cancer Staging Manual, Springer, New York.
Hong, S.M., Cho, H., Moskaluk, C.A., Yu, E., and Zaika, A.I. 2007. p63 and p73 expression in ext-rahepatic bile duct carcinoma and their clinical significance. J. Mol. Histol. 38: 167–175.
Hong, S.M., Kim, M.J., Pi, D.Y., Jo, D., Cho, H.J., Yu, E., and Ro, J.Y. 2005. Analysis of extrahe-patic bile duct carcinomas according to the New American Joint Committee on Cancer staging system focused on tumor classification problems in 222 patients. Cancer 104: 802–810.
Khan, S.A., Thomas, H.C., Toledano, M.B., Cox, I.J., and Taylor-Robinson, S.D. 2005. p53 Mutations in human cholangiocarcinoma: a review. Liver Int. 25: 704–716.
Lee, Y.C., Song, S.Y., Chung, J.B., Kang, J.K., and Park, I.S. 1996. p53 protein expression in extrahepatic bile duct cancer. Yonsei Med. J. 37: 112–117.
Leong, C.O., Vidnovic, N., DeYoung, M.P., Sgroi, D., and Ellisen, L.W. 2007. The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers. J. Clin. Invest. 117: 1370–1380.
Malhi, H., and Gores, G.J. 2006. Cholangiocarcinoma: modern advances in understanding a deadly old disease. J. Hepatol. 45: 856–867.
Momoi, H., Okabe, H., Kamikawa, T., Satoh, S., Ikai, I., Yamamoto, M., Nakagawara, A., Shimahara, Y., Yamaoka, Y., and Fukumoto, M. 2001. Comprehensive allelotyping of human intrahepatic cholangiocarcinoma. Clin. Cancer Res. 7: 2648–2655.
Munro, A.J., Lain, S., and Lane, D.P. 2005. P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br. J. Cancer 92: 434–444.
Murata, T., Nagasaka, T., Kamiya, J., Nimura, Y., Wakai, K., Yoshida, K., and Nakashima, N. 2002. P53 labeling index in cholangioscopic biopsies is useful for determining spread of bile duct carcinomas. Gastrointest. Endos. 56: 688–695.
Nagakawa, T., Kayahara, M., Ikeda, S., Futakawa, S., Kakita, A., Kawarada, H., Matsuno, M., Takada, T., Takasaki, K., Tanimura, H., Tashiro, S., and Yamaoka, Y. 2002. Biliary tract cancer treatment: results from the Biliary Tract Cancer Statistics Registry in Japan. J. HepatoBiliary-Pancreat. Surg. 9: 569–575.
Nathan, H., Pawlik, T.M., Wolfgang, C.L., Choti, M.A., Cameron, J.L., and Schulick, R.D. 2007. Trends in survival after surgery for cholangi-ocarcinoma: a 30-year population-based SEER database analysis. J. Gastrointest. Surg. 11: 1488–1496; discussion: 1496–1487.
Nomoto, K., Tsuneyama, K., Cheng, C., Takahashi, H., Hori, R., Murai, Y., and Takano, Y. 2006. Intrahepatic cholangiocarcinoma arising in cir-rhotic liver frequently expressed p63-positive basal/stem-cell phenotype. Pathol. Res. Pract. 202: 71–76.
Seyama, Y., and Makuuchi, M. 2007. Current surgical treatment for bile duct cancer. World J. Gastroenterol. 13: 1505–1515.
Suto, T., Sugai, T., Nakamura, S., Uesugi, N., Sasaki, R., Kanno, S., and Saito, K. 1997. Immunohistochemical detection of proliferating cell nuclear antigen and p53 expression in carcinoma of the extrahepatic bile duct. Oncology 54: 407–413.
Tan, G., Yilmaz, A., De Young, B.R., Behling, C., Lehman, A., and Frankel, W.L. 2004. Immunohistochemical analysis of biliary tract lesions. Appl. Immunohistochem. Mol. Morphol. 12: 193–197.
Tannapfel, A., Engeland, K., Weinans, L., Katalinic, A., Hauss, J., Mossner, J., and Wittekind, C. 1999. Expression of p73, a novel protein related to the p53 tumour suppressor p53, and apoptosis in cholangiocellular carcinoma of the liver. Br. J. Cancer 80: 1069–1074.
Vilgelm, A., El-Rifai, W., and Zaika, A. 2008. Therapeutic prospects for p73 and p63: Rising from the shadow of p53. Drug Resist. Updat. 11: 152–163.
Yang, B., House, M.G., Guo, M., Herman, J.G., and Clark, D.P. 2005. Promoter methylation profiles of tumor suppressor genes in intrahepatic and extrahepatic cholangiocarcinoma. Mod. Pathol. 18: 412–420.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer Science + Business Media B.V.
About this chapter
Cite this chapter
Zaika, A.I., Hong, SM. (2009). Extrahepatic Bile Duct Carcinoma: Role of the p53 Protein Family. In: Hayat, M.A. (eds) Liver Cancer. Methods of Cancer Diagnosis, Therapy and Prognosis, vol 5. Springer, Dordrecht. https://doi.org/10.1007/978-1-4020-9804-8_33
Download citation
DOI: https://doi.org/10.1007/978-1-4020-9804-8_33
Publisher Name: Springer, Dordrecht
Print ISBN: 978-1-4020-9803-1
Online ISBN: 978-1-4020-9804-8
eBook Packages: MedicineMedicine (R0)